Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company, creating personalized therapeutics for patients with cancer. Kura’s pipeline consists of four potent and selective small molecule drug candidates targeting driver oncogenes or signaling pathways associated with cancer, with development programs designed for rapid clinical readout and accelerated development and commercialization. They focus on compounds where improved outcomes are associated with specific biomarkers to realize superior clinical outcomes.

<< Portfolio